The Japanese authority PMDA (Pharmaceutical and Medical Device Agency) which instituted a Warning Letter system in September 2025 has issued its first Warning Letter on 1 September 2026 to a contract manufacturer of generic pharmaceuticals in Japan’s Wakayama prefecture.

The new WL system represents a strengthening of government authority in conducting inspections (including district inspections).

Similar to the US, PMDA Warning Letters contain the name of the company, its address, items of non-conformity and the short history related to the observation.

In the PMDA website you can find:

  • All company names receiving PMDA inspections since September 2025.
  • All Warning Letters issued since September 2025.

In the first Warning Letter, two non-conformities are cited and three instances of inadequate handling of stability testing lead the list:

  1. When a stability result became OOS, but it was fraudulently reported to the Marketing Authorization Holder (MAH) to have a value within specifications.
  2. Some stability test methods were not performed, but results were recorded as if they were performed and were within specifications.
  3. A root cause of OOS was not investigated and instead, results using a different reference sample were recorded.

The PMDA noted that administrative measures should follow.

Share This Article with the Stability Community!

Share your questions and experiences

A stabilitarian encounters new situations every day. StabilityHub’s discussion forums give Stabilitarians an opportunity to ask questions and offer solutions to specific scenarios. Join in the conversations with other Stabilitiarians and share your knowledge!

A stabilitarian encounters new situations every day. StabilityHub’s discussion forums give Stabilitarians an opportunity to ask questions and offer solutions to specific scenarios. Join in the conversations with other Stabilitiarians and share your knowledge!